EPAS1 and cancer: Upregulation of HIF-2α-mediated cancer pathways was reported to associate with advanced stage features such as malignant transformation, epithelial-mesenchymal transition, and VEGF resistance in a variety of cancers, especially gastric cancer [31], clear cell renal cell cancer (ccRCC) [32], and pancreatic cancer [33].